Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia

American Journal of Cardiology

Volumn 107, Issue 6, 2011, Pages 898-905

  Goldberg, Anne C ^a   Bittner, Vera ^b   Pepine, Carl J ^c   Kelly, Maureen T ^d   Thakker, Kamlesh ^d   Setze, Carolyn M ^d   Lele, Aditya ^d   Sleep, Darryl J ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ESTRADIOL; FENOFIBRIC ACID; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79952314059     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.11.009     Document Type: Article

References (23)

1. American Heart Association Statistical Fact Sheet: "Women and Cardiovascular DiseaseStatistics 2010." www.americanheart.org/downloadable/ heart/1260905040318FS10WM10.pdf Accessed: January 21, 2010
2. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr, W.C. Cushman, D.G. Simons-Morton, R.P. Byington ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
4. V.G. Athyros, A.A. Papageorgiou, V.V. Athyrou, D.S. Demitriadis, and A.G. Kontopoulos Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia Diabetes Care 25 2002 1198 1202 (Pubitemid 41071172)
5. P.N. Durrington, J. Tuomilehto, A. Hamann, D. Kallend, and K. Smith Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia Diabetes Res Clin Pract 64 2004 137 151 (Pubitemid 38456692)
6. S.M. Grundy, G.L. Vega, Z. Yuan, W.P. Battisti, W.E. Brady, and J. Palmisano Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) Am J Cardiol 95 2005 462 468 (Pubitemid 40247539)
7. P.H. Jones, H.E. Bays, M.H. Davidson, M.T. Kelly, S.M. Buttler, C.M. Setze, D.J. Sleep, and J.C. Stolzenbach Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins Clin Drug Invest 28 2008 625 634
8. P.H. Jones, M.H. Davidson, M.L. Kashyap, M.T. Kelly, S.M. Buttler, C.M. Setze, D.J. Sleep, and J.C. Stolzenbach Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study Atherosclerosis 204 2009 208 215
9. K.K. Koh, M.J. Quon, S.H. Han, W.J. Chung, J.Y. Ahn, Y.H. Seo, I.S. Choi, and E.K. Shin Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia J Am Coll Cardiol 45 2005 1649 1653 (Pubitemid 40704501)
10. A.C. Goldberg, H.E. Bays, C.M. Ballantyne, M.T. Kelly, S.M. Buttler, C.M. Setze, D.J. Sleep, and J.C. Stolzenbach Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia Am J Cardiol 103 2009 515 522
11. S.M. Mohiuddin, C.J. Pepine, M.T. Kelly, S.M. Buttler, C.M. Setze, D.J. Sleep, and J.C. Stolzenbach Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study Am Heart J 157 2009 195 203
12. M.S. Kipnes, E.M. Roth, J.M. Rhyne, C.M. Setze, A. Lele, M.T. Kelly, D.J. Sleep, and J.C. Stolzenbach Year 2 assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study Clin Drug Invest 30 2010 51 61
13. H.E. Bays, P.H. Jones, S.M. Mohiuddin, M.T. Kelly, H. Sun, C.M. Setze, S.M. Buttler, D.J. Sleep, and J.C. Stolzenbach Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia J Clin Lipidol 2 2008 426 435 (Pubitemid 352795715)
14. P.H. Jones, M.H. Davidson, A.C. Goldberg, C.J. Pepine, M.T. Kelly, S.M. Buttler, C.M. Setze, A. Lele, D.J. Sleep, and J.C. Stolzenbach Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies J Clin Lipidol 3 2009 125 137
15. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y.A. Kesaniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, and M. Laakso Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
16. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, and G. Steiner Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493 (Pubitemid 40341327)
17. V. Manninen, M.O. Elo, M.H. Frick, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, H. Menp, M. Mlknen, M. Mnttri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjblom, and E.A. Nikkil Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study JAMA 260 1988 641 651
18. Israeli Society for Prevention of Heart Attacks Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
19. B.J. Ansell, G.C. Fonarow, K.C. Maki, M.R. Dicklin, M. Bell, and M.H. Davidson Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey Am Heart J 152 2006 976 981 (Pubitemid 44637134)
20. V. Bittner Perspectives on dyslipidemia and coronary heart disease in women: an update Curr Opin Cardiol 21 2006 602 607 (Pubitemid 44624547)
21. S.N. Hayes Preventing cardiovascular disease in women Am Fam Physician 74 2006 1331 1340 (Pubitemid 44608182)
22. T.M. Wizemann, and M.-L. Pardue Exploring the Biological Contributions to Human Health: Does Sex Matter? 2001 National Academies Press Washington, DC
23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection Evaluation, and treatment of High Blood cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421